A team at Guy’s and St Thomas’ NHS Foundation Trust in London set out to close this gap with a structured, age-adapted initiative known as the GOLD diabetes enhanced monitoring pathway, developed within the Geriatric Oncology Liaison Development clinic. Reporting their work in the European Geriatric Medicine journal, the researchers describe a quality improvement project conducted between February 2022 and June 2025, in which a multidisciplinary group of geriatricians, oncologists, diabetologists and clinical nurse specialists translated national guidance from the UK Chemotherapy Board and the Joint British Diabetes Societies for Inpatient Care into a practical, locally tailored system for older patients at intermediate risk of steroid-induced hyperglycaemia.

The pathway began with careful risk stratification. Patients were classified as low risk if they had an HbA1c below 48 mmol/mol and no history of diabetes, and were followed by their oncology team and general practitioner. High-risk patients, including those on insulin, those with HbA1c of 64 mmol/mol or above, glucose readings of 15 mmol/L or higher, pancreatic cancer, or a previous episode of steroid-induced hyperglycaemia, were referred directly to specialist diabetes services. The intermediate group, typically those with HbA1c between 48 and 63 mmol/mol or capillary glucose between 11 and 14.9 mmol/L, or patients with diabetes managed on oral agents who did not meet high-risk criteria, became the focus of the GOLD pathway.

Once enrolled, each patient received a capillary blood glucose meter and personalised education from a geriatric clinical nurse specialist, delivered face to face or by telephone within days of referral, because the interval between referral and the start of systemic anti-cancer therapy is often extremely short. Education covered the symptoms of high and low blood sugar, how to recognise diabetes emergencies, glucose targets, and practical demonstrations of the meter, all calibrated to each patient’s health literacy, cognition and physical abilities, with caregivers involved where necessary. During every treatment cycle, patients checked their glucose on the day of steroid administration and the following two days, before breakfast and before the evening meal, a schedule designed to capture the late-afternoon and evening peaks characteristic of steroid-induced hyperglycaemia.

Telephone follow-up by nurse specialists after each cycle formed the backbone of the monitoring system. The team reviewed all glucose readings, assessed food intake and treatment side effects, and applied decision-making algorithms for intervention. Hyperglycaemia was defined as at least two readings above 15 mmol/L, and hypoglycaemia as any reading below 4 mmol/L. When medication was required, the protocol favoured gliclazide, a sulphonylurea that directly stimulates insulin secretion and thereby counteracts the steroid-driven suppression of pancreatic beta-cell function. The team deliberately adopted a higher intervention threshold of 15 mmol/L, compared with the 12 mmol/L in national guidance, reflecting broader glycaemic targets for older people and a conscious effort to avoid hypoglycaemia and its consequences, particularly in patients with poor oral intake or renal impairment.

The implementation itself was iterative. The pathway was refined through seven Plan-Do-Study-Act cycles between 2022 and 2023, each incorporating feedback from healthcare professionals and addressing specific local barriers such as the feasibility of glucose measurement, intervention thresholds and the medication titration process. Risk criteria were sharpened over successive cycles, with the glucose range adjusted from 12–20 to 11–15 mmol/L and the HbA1c range expanded from 48–59 to 48–64 mmol/mol. Fortnightly multidisciplinary meetings were introduced from January 2023 to review complex cases, and the geriatric nursing team grew increasingly autonomous in managing intermediate-risk patients, reducing the burden on specialist diabetes services while retaining rapid access to expert advice.

In total, 126 patients were enrolled, with a median age of 74 years, 58% male, and 77% living with pre-existing diabetes. The most common tumour sites were the oesophagus, colon and breast, and 94% received chemotherapy as their primary systemic anti-cancer therapy, most commonly supported by dexamethasone at a median daily dose of 8 mg for the first four days of each cycle, chiefly for its anti-emetic and anti-allergic properties. Comprehensive geriatric assessment data, available for 81% of participants, revealed a largely pre-frail population with a median Clinical Frailty Scale score of 3, and identified malnutrition in 46% of the cohort, alongside social isolation, functional impairment and recent falls in smaller proportions. Personalised geriatric interventions, spanning physiotherapy, occupational therapy, dietary support and medication management, were implemented for the vast majority of those with identified impairments.

The results paint a picture of a pathway that is both feasible and safe. Clinical advice on diabetes management was provided to 89% of patients, and diabetes medication intervention was required in 32%, with gliclazide initiated or escalated in 92% of those cases. Women and patients with pre-existing diabetes were significantly more likely to need medication. Critically, only three hypoglycaemic events occurred, all asymptomatic and all managed without clinical consequences. Among 35 unplanned hospital admissions within a year, only two were related to hyperglycaemia, and there were no episodes of diabetic ketoacidosis or hyperosmolar hyperglycaemic syndrome, and no admissions for hypoglycaemia. During a median follow-up of 300 days, 41 patients died, but mortality was associated with metastatic disease, malnutrition and social isolation rather than with glycaemic control or diabetes intervention, suggesting that proactive metabolic monitoring did not add risk in this fragile population.

The pathway also influenced cancer treatment itself in measurable ways. Steroid regimens were modified for 24% of patients, almost always involving dose reductions driven by hyperglycaemia, and in 80% of those cases the adjustment was linked to the need for diabetes medication. While steroid reduction triggered treatment toxicity symptoms in four patients, leading to early discontinuation or dose reduction of the anti-cancer protocol in two, the overall signal was one of balance: oncologists could taper steroids with confidence knowing that a safety net existed for the metabolic consequences. Notably, secondary referrals to the diabetes team fell dramatically over the project period, from 36% of patients enrolled in 2022 to just 5% in 2025, evidence that the geriatric team’s growing expertise was absorbing demand that would otherwise have overwhelmed specialist services.

The authors are candid about limitations. The single-centre design, the predominance of pre-frail patients, the absence of a comparator group and the use of clinical rather than validated tools for some geriatric domains all constrain generalisability, and under-ascertainment of nocturnal or asymptomatic glycaemic excursions cannot be excluded with intermittent fingerstick testing. Even so, the team argues that the GOLD pathway offers a robust, patient-centred model for integrating geriatric, oncology and diabetes care, aligned with national and international recommendations for multidisciplinary management of older adults with complex needs. Future priorities include multi-centre validation, comparative and randomised designs to confirm effectiveness, integration of continuous glucose monitoring and digital health tools to reduce nursing workload, evaluation of patient-reported outcomes and cost-effectiveness, and incorporation of patient feedback to improve usability for those who struggle with glucometer technology. If those steps succeed, structured diabetes monitoring could become a standard component of geriatric oncology, ensuring that the steroids that help fight cancer no longer silently undermine the patients receiving them.

Subject of Research: A quality improvement project evaluating an age-adapted, multidisciplinary diabetes monitoring pathway for older adults with cancer undergoing steroid-based systemic anti-cancer therapy.

Article Title: Improving diabetes management in older adults with cancer: a quality improvement project to enhance monitoring during steroid-based systemic anti-cancer therapy

Article References: Liuu, E., Evans, R., Bassas-Letissier, N., Amaratunga, G., Compton, S., Georgiou, A., Kalsi, T., Liu, Y.-F., Maguire, J., Nottage, C., Rush, H. L., & Welch, C. (2026). Improving diabetes management in older adults with cancer: a quality improvement project to enhance monitoring during steroid-based systemic anti-cancer therapy. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01585-w

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01585-w

Keywords: geriatric oncology, diabetes, steroid-induced hyperglycaemia, systemic anti-cancer therapy, quality improvement, multidisciplinary care, gliclazide, blood glucose monitoring, older adults, comprehensive geriatric assessment, hypoglycaemia, cancer treatment

The biological rationale is compelling. Diabetes and heart failure are tightly intertwined: chronically elevated glucose, insulin resistance, and metabolic inflammation damage the heart muscle and blood vessels, causing many patients to progress rapidly from silent cardiac dysfunction to overt, symptomatic heart failure. Epidemiological analyses, including the Atherosclerosis Risk in Communities study, have shown that diabetes accelerates the progression of heart failure, and meta-analyses confirm a substantially elevated risk of new-onset and recurrent heart failure in people with diabetes. Yet heart failure remains notoriously under-recognized in this population; a systematic review published in the Journal of Cardiac Failure documented how frequently the condition is misdiagnosed, often because early symptoms are vague or attributed to other causes.

NT-proBNP—N-terminal pro-B-type natriuretic peptide—is a fragment of a hormone precursor released by heart muscle cells when they are stretched or under pressure. Because the peptide is cleared by the kidneys and is more stable in blood than its cousin BNP, it has become the workhorse biomarker for cardiac stress. Decades of evidence, from the International Collaborative of NT-proBNP study to the Heinz Nixdorf Recall Study, show that elevated concentrations predict cardiovascular events and death, and that NT-proBNP outperforms BNP for predicting first cardiovascular events in the general population. In people with diabetes, serial measurements in trials such as EXAMINE and large biobank analyses from Hong Kong have demonstrated that the biomarker sharply improves prediction of cardiorenal complications, including in patients without any known cardiac disease.

The pivotal shift came when the American Diabetes Association formally endorsed biomarker screening for Stage B heart failure—the asymptomatic phase of cardiac dysfunction defined in the universal classification of heart failure. Under the ADA Standards of Care, measurement of natriuretic peptides is now recommended to identify people with diabetes whose hearts are already straining silently, opening a window for intervention with modern cardioprotective therapies before irreversible damage occurs. Landmark randomized trials underpin this approach: the STOP-HF trial in Ireland showed that natriuretic peptide-based screening combined with collaborative care reduced incident heart failure, while the PONTIAC trial in Austria demonstrated similar benefit in diabetic patients without prior cardiac disease. More recently, the STRONG-DH pilot study tested a risk-based screening and treatment pathway guided by NT-proBNP in diabetes.

What makes the new review distinctive is its pragmatic focus on implementation rather than discovery. The expert panel, convened to share real-world experience, concluded that no single blueprint will work everywhere. Instead, any national or regional early detection program must weigh four parameters: the patient pathway from screening to diagnosis and treatment; the availability of laboratory and specialist resources; the educational needs of frontline clinicians who must interpret and act on test results; and cost-effectiveness within local payment systems. The authors emphasize that a multipronged approach with a clear evaluation, diagnosis, and treatment pathway is essential for NT-proBNP programs to take root globally.

Country-specific experiences illustrate both the promise and the friction of implementation. Consensus statements have emerged from professional societies in Portugal, Switzerland, and Spain, each tailoring screening populations and biomarker thresholds to local epidemiology and health system capacity. In India, real-world data from a tertiary care center demonstrated the feasibility of occult heart failure screening with NT-proBNP in type 2 diabetes, while Irish investigators have documented the prevalence and trajectory of elevated natriuretic peptides in high-risk diabetic populations. In Slovenia, educational initiatives have updated cardiologists and diabetologists on the value of the biomarker, and in the United States, institutional guidelines such as the University of Michigan health system’s protocol for adults with diabetes over fifty show how electronic medical records can embed screening into routine diabetes visits.

The review also confronts the interpretive subtleties that can derail screening programs. NT-proBNP concentrations are influenced by age, sex, renal function, atrial fibrillation, and obesity, and chronic kidney disease—a frequent diabetes complication—can raise levels independently of cardiac status. Studies comparing diagnostic accuracy in chronic kidney disease, quantifying the effect of renal dysfunction on BNP and NT-proBNP ratios, and examining obesity’s impact on diagnostic cut-offs all underscore that thresholds must be fine-tuned rather than applied mechanically. The panel argues that this fine-tuning of the population in scope and the biomarker interpretation thresholds is precisely what will determine whether screening programs are sustainable.

Economics, the panel stresses, may ultimately decide adoption. A series of cost-effectiveness analyses spanning the United States, Brazil, Hong Kong, and China have evaluated whether NT-proBNP-guided screening pays for itself by preventing expensive hospitalizations and advanced disease. Early results suggest that identifying Stage B heart failure and initiating guideline-directed medical therapy—now including SGLT2 inhibitors, which trials like CREDENCE and canagliflozin biomarker studies show also lower NT-proBNP—can be cost-effective, but the calculations depend heavily on local drug prices, laboratory costs, and the structure of primary care. The review’s authors argue that health technology assessment should be built into program design from the outset rather than retrofitted after launch.

The stakes are enormous. The International Diabetes Federation’s latest atlas estimates that well over half a billion adults live with diabetes, a number projected to climb steeply, and each of those individuals carries a markedly elevated risk of progressing to heart failure. Because early identification and management demonstrably improve outcomes, the gap between guideline recommendations and universal practice represents preventable morbidity and death on a global scale. The review’s central message is one of cautious optimism: the biomarker exists, the trials support screening, the guidelines endorse it, and national consensus documents are accumulating. What remains is the unglamorous but decisive work of building pathways, training clinicians, aligning resources, and proving value—so that a routine blood draw at a diabetes check-up becomes, everywhere, an early warning system for the heart.

Subject of Research: Implementation of NT-proBNP biomarker testing for early detection of heart failure in people with diabetes

Article Title: Translating Guidelines into Practice: Implementation of NT-proBNP Testing for Early Heart Failure Detection in Diabetes, a Narrative Review

Article References: Pop-Busui, R., Cebrián-Cuenca, A., Ceponis, J., Da Porto, A., dos Santos, J., Gavina, C., Gastaldi, G., Janež, A., Joshi, A., McDonald, K., Meyer, G., Rotar Pavlič, D., Ükinç, K., & Januzzi, J. L. (2026). Translating Guidelines into Practice: Implementation of NT-proBNP Testing for Early Heart Failure Detection in Diabetes, a Narrative Review. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10791-y

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10791-y

Keywords: NT-proBNP, heart failure, diabetes, Stage B heart failure, biomarker screening, American Diabetes Association guidelines, cardiovascular risk, early detection, implementation, cost-effectiveness, narrative review, cardiometabolic medicine

The first concern centers on who was actually included in the meta-analysis. According to the commentary, the review stated that eligible participants were individuals with type 1 or type 2 diabetes mellitus, yet studies involving people with gestational diabetes and prediabetes were subsequently included in the analysis. The corresponding PROSPERO registration record, which documents the review protocol in advance, defined the eligible population simply as subjects with diabetes mellitus, without explicitly specifying these additional groups. Fuentes-Barría argues that this drift between the registered protocol and the executed review matters because gestational diabetes and prediabetes differ substantially from established type 1 and type 2 diabetes in pathophysiology, baseline cardiovascular and metabolic risk, and clinical management. Pooling these distinct populations, he contends, inflates clinical heterogeneity and weakens the applicability of the combined estimates to any single patient group.

A second and equally consequential issue involves the nature of the interventions themselves. Not all of the trials included in the meta-analysis tested zinc alone. Some interventions combined zinc with other micronutrients or bioactive compounds, a fact the original authors themselves acknowledged when they conceded that such co-interventions make it difficult to attribute observed effects specifically to zinc. The commentary argues that mixing zinc-only trials with multicomponent interventions introduces another layer of clinical heterogeneity and complicates the interpretation of pooled effects. To resolve this ambiguity, the commentator recommends sensitivity analyses that exclude multicomponent interventions, which would reveal whether the reported benefits survive when the analysis is restricted to trials in which zinc is the sole active agent. Without such analyses, he suggests, readers cannot judge the robustness of the pooled estimates or the extent to which zinc itself deserves credit.

Statistical heterogeneity represents the third pillar of the critique. The commentary highlights that several pooled outcomes showed substantial or even considerable heterogeneity across the included trials. The most striking example is plasma zinc concentration, where the I-squared statistic reached 99 percent, meaning virtually all of the variability between studies reflects real differences rather than chance. Other metabolic and inflammatory outcomes also demonstrated high heterogeneity. Although the original authors applied random-effects models and conducted meta-regression in an attempt to account for this variability, the commentary notes that substantial residual heterogeneity remained unexplained. Under these circumstances, Fuentes-Barría argues, a single pooled estimate carries limited clinical meaning, and its generalizability to diverse patient populations, dosing regimens and treatment durations should be interpreted with pronounced caution.

The fourth concern targets the meta-regression analyses themselves. The original review performed multiple meta-regressions examining age, sex, zinc dose and intervention duration as potential effect modifiers, despite several outcomes being based on a limited number of studies. This is problematic, the commentary explains, because meta-regression generally requires an adequate number of studies per moderator variable to produce reliable results. The Cochrane Handbook, the field’s leading methodological reference, advises caution when fewer than ten studies are available for such analyses. Beyond official guidance, methodological research has shown that meta-regression analyses are frequently undermined by overfitting and other pitfalls that can generate misleading findings. A meta-epidemiological study cited in the commentary found that most published meta-regressions based on aggregate data suffer from such methodological problems. Given the limited number of trials and the multiple moderators examined, the commentator concludes that these dose-response and subgroup associations should be treated as exploratory and hypothesis-generating rather than confirmatory evidence.

Perhaps the most clinically pointed criticism concerns the gap between the review’s title and its actual findings. The meta-analysis did not demonstrate significant improvements in fasting plasma glucose or HbA1c, the two canonical measures of glycemic control, despite the title emphasizing glycemic control as a primary outcome. Instead, statistically significant effects were observed primarily for surrogate markers, including circulating insulin levels, HOMA-IR as a measure of insulin resistance, C-reactive protein as an inflammatory marker, and various oxidative stress biomarkers. The commentary argues that these statistically significant shifts in surrogate endpoints should not automatically be equated with clinically meaningful improvements in diabetes control or with outcomes that matter to patients, such as reduced complications, improved quality of life or decreased mortality. Research on surrogate endpoints in diabetes trials has repeatedly shown that changes in biomarkers do not always translate into tangible clinical benefit, making this distinction far more than a semantic quibble.

The commentary’s overall message is one of measured skepticism rather than outright rejection. Fuentes-Barría explicitly frames his remarks as a constructive contribution to a clinically relevant topic, acknowledging the importance of the question the original review addressed. Zinc is an essential trace element involved in insulin synthesis, storage and secretion, as well as in antioxidant defense mechanisms, which provides a plausible biological rationale for studying its supplementation in diabetes. However, plausibility of mechanism cannot substitute for methodological rigor in the evidence synthesis that is supposed to translate biology into clinical recommendations. The commentary suggests that the enthusiasm generated by statistically significant pooled effects on biomarkers risks outpacing what the underlying trial data can actually support.

To strengthen the evidence base, the commentator proposes a concrete path forward. Stratified and sensitivity analyses by diabetes phenotype would clarify whether zinc exerts different effects in type 1 diabetes, type 2 diabetes, gestational diabetes and prediabetes, populations whose distinct metabolic contexts could plausibly modify any treatment effect. Restricting analyses to zinc-only interventions would isolate the specific contribution of the mineral from that of co-administered compounds. And prioritizing clinically relevant glycemic outcomes, particularly HbA1c and fasting glucose, over surrogate biomarkers would anchor the conclusions in endpoints that directly inform patient care. These refinements, the commentary argues, could substantially improve both the validity and the clinical interpretability of future updates to this body of evidence.

The exchange is a timely reminder of how meta-analyses, often perceived as the pinnacle of the evidence hierarchy, remain only as reliable as the methodological choices embedded within them. Decisions about which populations to pool, which interventions to combine, how to handle heterogeneity and how many moderator analyses to run can each shift the final estimates and the confidence readers place in them. For the growing number of people with diabetes worldwide who may be considering zinc supplements, and for the clinicians who advise them, the commentary underscores that the current evidence supports caution: meaningful effects on the measures that define diabetes control have not yet been demonstrated, and the significant biomarker changes reported so far should be viewed as signals worth further investigation rather than proof of clinical benefit. As the field awaits more rigorously designed and analyzed syntheses, the debate illustrates the self-correcting nature of scientific publishing, where critical commentary serves as an essential quality-control mechanism for evidence that ultimately shapes real-world health decisions.

Subject of Research: Methodological critique of a meta-analysis on zinc supplementation in diabetes

Article Title: Comment on ‘Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes’

Article References: Fuentes‐Barría, H. (2026). Comment on ‘Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes’. Endocrinology, Diabetes & Metabolism, 9(5), Article e70328. https://doi.org/10.1002/edm2.70328

Image Credits: AI Generated

DOI: 10.1002/edm2.70328

Keywords: zinc supplementation, diabetes, meta-analysis, glycemic control, insulin resistance, HbA1c, inflammation, oxidative stress, clinical heterogeneity, meta-regression, Comment, Effects

The biological target of the study is a population of cells known as corpus cavernosum smooth muscle cells, or CCSMCs, which form the muscular scaffolding of the erectile tissue. During an erection, these cells must relax in a coordinated fashion to allow the spongy chambers of the penis to fill with blood, and their ability to do so depends on maintaining what biologists call a contractile phenotype, a differentiated state in which the cell is packed with the contractile proteins that respond to vascular signals. Under the chronic oxidative stress of diabetes, however, these cells can undergo what researchers term phenotypic switching, abandoning their contractile identity in favor of a synthetic state characterized by proliferation, migration and the production of extracellular matrix. In the synthetic state, the cells lose the very proteins, such as alpha-smooth muscle actin and smooth muscle myosin heavy chain, that give them their mechanical function, and they instead express markers like osteopontin and proliferating cell nuclear antigen. This transition is increasingly recognized as a pivotal event in the progression of diabetes-related erectile dysfunction, but the regulatory circuits that connect diabetic stress to this switch have remained poorly understood.

To probe those circuits, the team began by examining the corpus cavernosum of rats made diabetic through injection of streptozotocin, a chemical that selectively destroys insulin-producing cells and produces a model of type 1 diabetes widely used in erectile dysfunction research. In these animals, the researchers found that expression of ARHGAP10, a member of the Rho GTPase-activating protein family, was significantly reduced compared with healthy controls. ARHGAP10 is known to function as a brake on Rho GTPase signaling, a pathway that governs cytoskeletal dynamics and smooth muscle contraction, so its loss in diabetic tissue immediately suggested a possible contributor to the erosion of contractile function.

The researchers then tested whether restoring ARHGAP10 could reverse the damage. Using adenoviral vectors delivered directly into the erectile tissue, they overexpressed the Arhgap10 gene in the cavernous tissue of diabetic rats and assessed erectile function by measuring intracavernosal pressure relative to mean arterial pressure, the standard physiological readout of erection quality in rodent models. The results were striking: animals receiving the ARHGAP10 vector showed measurably improved erectile responses compared with diabetic controls, and molecular analysis of their cavernous tissue revealed a marked suppression of the synthetic phenotypic switch, with contractile markers preserved and synthetic markers held in check.

To understand how ARHGAP10 exerts these effects, the team turned to RNA sequencing of primary CCSMCs grown in the laboratory. This transcriptomic survey identified G0S2, the G0/G1 switch gene 2, as a key downstream effector of ARHGAP10. G0S2 is a small protein with established roles in cell cycle control and lipid metabolism, best known in other contexts for its interaction with adipose triglyceride lipase, but its involvement in smooth muscle phenotypic regulation had not been appreciated. Co-immunoprecipitation assays then confirmed that ARHGAP10 and G0S2 physically interact, forming a protein complex within the cells. This physical association proved to be more than a curiosity; it was the mechanistic linchpin of the entire pathway.

The connection to mitochondria emerged when the researchers examined the organelles themselves. Mitochondria are the power plants of the cell, and their functional state is routinely assessed by measuring membrane potential, the electrical charge across the inner mitochondrial membrane that drives energy production, along with the generation of reactive oxygen species, the chemically reactive molecules that accumulate when the electron transport chain falters, and the ultrastructural appearance of the organelles under transmission electron microscopy. In diabetic conditions, CCSMCs showed the classic signature of mitochondrial dysfunction: collapsed membrane potential, excessive mitochondrial reactive oxygen species production and damaged ultrastructure. Remarkably, restoring ARHGAP10, through its interaction with G0S2, rescued all three parameters, restoring membrane potential, taming the overproduction of mitochondrial ROS and improving the structural integrity of the organelles.

The causal chain was then tested from both directions. When the researchers knocked down G0S2 in cultured cells, the protective effects of ARHGAP10 on the contractile phenotype were abolished, demonstrating that G0S2 is necessary for ARHGAP10 to work. Conversely, when G0S2 alone was overexpressed in the cavernous tissue of diabetic rats, without any ARHGAP10 manipulation, the treatment effectively reproduced the therapeutic benefits of ARHGAP10, restoring erectile function and preserving the contractile phenotype of the smooth muscle cells. This sufficiency experiment is particularly significant because it elevates G0S2 from a mere correlate to a genuine therapeutic target, one that sits downstream of ARHGAP10 and could potentially be manipulated directly by drugs.

The clinical context of these findings is important. Current first-line therapy for erectile dysfunction consists of phosphodiesterase type 5 inhibitors, the drug class that includes sildenafil, which work by amplifying the nitric oxide signaling that drives blood flow into the penis. These drugs are effective for many patients, but a substantial fraction of men with diabetes respond poorly to them, largely because diabetes ravages the nerves, blood vessels and smooth muscle that the drugs depend upon. By targeting the underlying cellular degeneration rather than the downstream signaling, an ARHGAP10-G0S2-based strategy would represent a fundamentally different approach, one that aims to preserve or restore the contractile machinery of the erectile tissue itself rather than simply coax more blood through a failing system.

Several technical details of the study strengthen its conclusions. The use of both in vivo adenoviral gene delivery and in vitro primary cell culture allowed the team to triangulate their findings across experimental systems, and the comprehensive mitochondrial assessment, spanning membrane potential measured with the JC-1 fluorescent probe, reactive oxygen species quantification and transmission electron microscopy of organelle ultrastructure, provided converging evidence that mitochondrial rescue is the operative mechanism. The team also traced the pathway’s connection to canonical smooth muscle contraction signaling, examining the RhoA pathway and its downstream effector MYPT1, thereby situating ARHGAP10 within the broader Rho signaling architecture that governs smooth muscle tone. Supplementary experiments further showed that ARHGAP10 overexpression attenuates the proliferation and migration of CCSMCs induced by platelet-derived growth factor-BB, a potent driver of phenotypic switching, and that pharmacological knockdown of G0S2 promotes switching on its own, reinforcing the necessity of this gene for maintaining the contractile state.

As with any preclinical rodent study, the road from these findings to human therapy is long, involving the development of deliverable interventions, safety testing and clinical trials. Gene therapy approaches for erectile dysfunction have been explored for decades without reaching routine clinical use, and the adenoviral vectors employed here are research tools rather than ready-made medicines. Nevertheless, the identification of a necessary and sufficient downstream mediator in G0S2 offers a concrete molecular handle that small molecules or other modalities could eventually target. The work also adds to a growing appreciation that mitochondrial dysfunction is not merely a byproduct of diabetic tissue damage but an active driver of it, and that restoring mitochondrial health can reverse pathological cellular reprogramming. For the millions of men whose diabetes has eroded both their vascular health and their quality of life, the demonstration that a single protein interaction can restore erectile function in a disease model is a compelling proof of concept, and a reminder that some of the most promising advances in medicine come from following the molecular threads wherever they lead, even into the smallest organelles of the body’s most private machinery.

Subject of Research: The role of the ARHGAP10-G0S2 protein interaction in preserving mitochondrial function and contractile phenotype of corpus cavernosum smooth muscle cells to ameliorate diabetic erectile dysfunction

Article Title: ARHGAP10-G0S2 interaction attenuates phenotypic switching of corpus cavernosum smooth muscle cells by restoring mitochondrial function, thereby ameliorating erectile dysfunction in diabetic rats

Article References: Liao, Z.-Q., Luo, J.-Q., Xiang, Y.-R., Liu, Y.-H., Lu, B.-X., Luo, C.-Y., He, H.-Y., Zhou, X.-C., Pan, M.-X., He, S.-H., Wei, A.-Y., & Zhang, H.-B. (2026). ARHGAP10-G0S2 interaction attenuates phenotypic switching of corpus cavernosum smooth muscle cells by restoring mitochondrial function, thereby ameliorating erectile dysfunction in diabetic rats. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08942-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08942-0

Keywords: erectile dysfunction, diabetes, ARHGAP10, G0S2, mitochondrial dysfunction, phenotypic switching, smooth muscle cells, corpus cavernosum, reactive oxygen species, diabetic rats, Journal of Translational Medicine, Rho signaling

Diabetes mellitus is far more than a disorder of blood sugar. Persistent hyperglycemia triggers a slow, systemic assault on tissues throughout the body, and while the kidneys, nerves, and retina receive most of the attention, the spleen quietly suffers as well. This fist-sized lymphoid organ orchestrates innate and adaptive immunity, filters aged red blood cells from circulation, and serves as a critical reservoir of immune cells. When the spleen falters, the consequences ripple outward: anemia worsens, infection susceptibility climbs, and the delicate balance between pro-inflammatory and anti-inflammatory signaling collapses. Earlier studies have documented splenic shrinkage, lymphoid degeneration, and immune dysregulation in diabetic animals, but effective pharmacological protectants remain scarce.

The research team, led by Asma B. Omer of Princess Nourah bint Abdulrahman University together with collaborators across Saudi Arabia, Oman, and India, chose streptozotocin, or STZ, as their diabetes-inducing agent. STZ is a glucosamine-nitrosourea compound that selectively destroys insulin-producing pancreatic beta cells, producing a model of persistent hyperglycemia that closely mirrors the metabolic and oxidative burden of uncontrolled human diabetes. A single intraperitoneal dose of 50 milligrams per kilogram was sufficient to push the Wistar rats into a diabetic state, setting the stage for eight weeks of treatment with oral rufigallol at two doses, 10 and 20 milligrams per kilogram per day.

The baseline damage inflicted by STZ was comprehensive and sobering. Diabetic animals developed sustained elevation of fasting blood glucose alongside a measurable reduction in spleen weight, signaling tissue atrophy. Their hematological profiles deteriorated in a pattern familiar to clinicians: anemia, elevated white cell counts consistent with chronic inflammatory activation, and falling platelet numbers. Beneath these visible changes, the molecular machinery of the spleen was under coordinated attack. Levels of malondialdehyde, a canonical marker of lipid peroxidation, surged, and nitric oxide production climbed, both signatures of unchecked oxidative assault on cellular membranes and proteins.

Equally telling was the collapse of the spleen’s antioxidant shield. Superoxide dismutase, catalase, and reduced glutathione, the enzymatic and non-enzymatic sentinels that normally neutralize reactive oxygen species, were all significantly depleted in the diabetic animals. With antioxidant defenses eroded, the pro-inflammatory cascade gained momentum. The researchers measured markedly increased concentrations of interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma, coupled with suppression of the anti-inflammatory cytokines interleukin-2 and interleukin-4. At the top of this inflammatory hierarchy sat nuclear factor kappa B, NF-κB, the transcription factor that coordinates the expression of dozens of inflammatory genes, and it was strongly activated in the diabetic spleen.

The third prong of the injury was apoptosis, the controlled self-destruction of cells. In the diabetic spleens, the pro-apoptotic protein Bax and the execution enzyme caspase-3 were upregulated, while the anti-apoptotic guardian Bcl-2 was diminished. This shift in the Bax-to-Bcl-2 ratio pushed splenic cells, including the lymphocytes and macrophages that populate the white and red pulp, toward self-elimination. Histopathological examination confirmed the functional data at the tissue level, revealing marked disruption of the normal splenic architecture, with damage to the lymphoid follicles and red pulp structures that underpin the organ’s immune and filtration roles.

Rufigallol treatment turned this grim molecular picture around in a dose-dependent fashion. The higher dose of 20 milligrams per kilogram consistently outperformed the lower dose across nearly every endpoint. Treated animals showed significantly reduced fasting blood glucose, recovered spleen weight, and improved hematological indices, including corrections in the anemia, leukocytosis, and thrombocytopenia that had accompanied the diabetic state. At the biochemical level, the compound restored the depleted antioxidant arsenal, elevating superoxide dismutase, catalase, and glutathione while simultaneously driving down malondialdehyde and nitric oxide, evidence that it both quenched existing oxidative damage and rebuilt the spleen’s capacity to resist it.

The anti-inflammatory and anti-apoptotic effects were equally striking. Rufigallol suppressed the elevated pro-inflammatory cytokines and restrained NF-κB activation, dampening the transcriptional engine of splenic inflammation. At the same time, it rebalanced the apoptotic threshold: Bax and caspase-3 expression fell while Bcl-2 rose, shifting cells away from self-destruction and toward survival. Microscopic analysis of the treated spleens confirmed that these molecular changes translated into tangible structural recovery, with substantially improved preservation of the lymphoid architecture compared with untreated diabetic controls. The authors conclude that rufigallol protected the spleen by simultaneously targeting oxidative stress, inflammatory signaling, and the apoptotic pathway, three interlocking mechanisms that converge on tissue survival.

The choice of rufigallol is scientifically grounded rather than arbitrary. The compound, formally 1,2,3,5,6-pentahydroxy-9,10-anthraquinone, belongs to the anthraquinone family, a class of polyphenolic plant metabolites with a growing resume in metabolic research. Related anthraquinones such as emodin, rhein, and aloe-emodin have shown anti-diabetic, antioxidant, and immunomodulatory properties in prior preclinical studies, and the hydroxyl-rich structure of rufigallol makes it a potent electron donor capable of neutralizing free radicals directly. The polyphenol’s redox activity, the researchers note, aligns with the broader recognition that dietary and plant-derived polyphenols can modulate redox signaling, bioenergetics, and cell fate decisions in ways that synthetic antioxidants often cannot.

The findings carry meaningful implications for a global diabetes epidemic that now affects hundreds of millions of people and continues to expand. Because splenic dysfunction compounds the immune weakness already characteristic of diabetes, contributing to heightened infection risk and poorer vaccine responses, protecting this organ could have clinical value beyond the laboratory. The authors caution that these results derive from a rodent model, and translation to human therapy will require pharmacokinetic profiling, toxicity evaluation, and ultimately controlled clinical trials. Nevertheless, the study adds rufigallol to the short list of natural compounds with demonstrated, mechanistically resolved protection of lymphoid tissue in diabetes, and it strengthens the case that inexpensive plant-derived anthraquinones deserve closer scrutiny as adjunctive agents against the multi-organ toll of chronic hyperglycemia. The research was supported by Princess Nourah bint Abdulrahman University Researchers Supporting Project number PNURSP2026R854.

Subject of Research: Protective effects of the anthraquinone compound rufigallol against streptozotocin-induced splenic injury in diabetic rats

Article Title: Rufigallol attenuates splenic damage caused by STZ by targeting oxidative stress, inflammation, and the apoptosis pathway

Article References: Omer, A. B., Afzal, M., Rafeeq, M., Murad, H. A. S., Alzarea, S. I., Sayyed, N., Kazmi, I., & Al-Abbasi, F. A. (2026). Rufigallol attenuates splenic damage caused by STZ by targeting oxidative stress, inflammation, and the apoptosis pathway. 3 Biotech, 16(10), Article 419. https://doi.org/10.1007/s13205-026-05047-9

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05047-9

Keywords: rufigallol, diabetes, spleen, streptozotocin, oxidative stress, inflammation, apoptosis, NF-κB, anthraquinone, antioxidant, Bcl-2, caspase-3

The study, led by Cesar Camilo Calderon Torres and Yang Guo of Hebei Medical University together with Jiashuo Huang and Jie Chang of Capital Medical University, drew on the China Health and Retirement Longitudinal Study, one of the country’s most important population health surveys. The team followed 6,298 postmenopausal women across survey waves from 2011 to 2018, tracking whether and when they developed combinations of hypertension, diabetes, and dyslipidemia, the three metabolic conditions that together drive much of the global burden of cardiovascular disease. Metabolic multimorbidity was defined as the co-occurrence of two or more of these disorders, a state that is far more dangerous than any single condition alone because the diseases amplify one another’s effects on the heart, kidneys, and brain.

To measure the relationship between menopause timing and disease risk, the researchers categorized self-reported age at menopause into three groups: early menopause before age 45, normal menopause between 45 and 55, and late menopause after 55. They then applied Cox proportional hazards models, a statistical technique that estimates how a given exposure changes the rate at which an event occurs over time, adjusting for a battery of sociodemographic and lifestyle factors including education, residence, body mass index, and health behaviors. This adjustment is critical in observational research, because women with different menopause timing may also differ in weight, smoking habits, socioeconomic status, and access to healthcare, any of which could confound the apparent relationship.

The results were unambiguous for late menopause. Over 12,632 person-years of follow-up, 583 women developed metabolic multimorbidity, and those who experienced menopause after age 55 had a 48 percent higher risk of doing so compared with women whose menopause fell in the normal window. The adjusted hazard ratio of 1.48, with a 95 percent confidence interval of 1.08 to 2.02, indicates a statistically robust association. Perhaps even more telling was the dose-response analysis: each additional year of age at menopause was associated with a 2 percent increase in multimorbidity risk. Restricted cubic spline analyses, which model the shape of the relationship between exposure and outcome without forcing it into a straight line, supported a pattern in which risk climbs steadily with later menopause timing.

When the researchers broke the outcome down into its individual components, the picture became more nuanced. Late menopause was most strongly linked to diabetes, with a hazard ratio of 1.49, meaning women with late menopause had roughly a 49 percent higher risk of developing the disease. Hypertension showed a more modest but still detectable linear increase, with each additional year of menopause age raising risk by about 1 percent. Dyslipidemia, by contrast, showed no significant association with menopause timing. This pattern is biologically plausible: prolonged ovarian estrogen production influences fat distribution, insulin sensitivity, and glucose metabolism, and extended exposure may promote the gradual accumulation of visceral adiposity and insulin resistance that culminates in type 2 diabetes.

What makes the finding counterintuitive is the long-standing assumption that later menopause is cardioprotective. Estrogen is known to exert favorable effects on lipid profiles and vascular function during reproductive years, and early surgical or natural menopause has repeatedly been tied to elevated cardiovascular risk. The new study did not contradict that literature entirely, because early menopause showed no significant association with metabolic multimorbidity in this cohort, with a hazard ratio of 0.93 that crossed the line of statistical significance. Instead, the data suggest a more complex curve in which both ends of the menopause timing spectrum may carry different types of risk, with late menopause favoring metabolic disease and early menopause potentially favoring other cardiovascular outcomes that this study did not measure.

The authors also examined whether the association varied across subgroups defined by educational level or urban versus rural residence, and found no significant interactions. That consistency matters for public health planning in China, where the population is aging rapidly and metabolic diseases are rising in both cities and the countryside. If the relationship between late menopause and metabolic multimorbidity holds across social strata, then menopause timing could serve as a simple, zero-cost marker that clinicians can record during routine history-taking to identify women who warrant closer metabolic surveillance in later life.

Several caveats deserve attention. Age at menopause was self-reported, and recall error is a known limitation in retrospective studies of reproductive history, particularly among older women surveyed years after the event. The CHARLS cohort is community-dwelling and middle-aged to older, so the findings may not generalize to women who died before recruitment or who experienced very early surgical menopause. Observational designs also cannot rule out residual confounding by factors such as parity, breastfeeding history, oral contraceptive use, or hormone therapy, none of which can be fully captured in a general aging survey. And because the outcome was incident multimorbidity during a relatively short follow-up window, longer studies will be needed to confirm whether the association persists and strengthens with age.

Even with those limitations, the study offers a valuable reframing of menopause as a metabolic event, not merely a reproductive one. The menopausal transition is increasingly recognized as a window of heightened vulnerability, when shifts in estrogen, body composition, and sleep converge to accelerate cardiometabolic risk. By showing that the timing of that transition predicts the likelihood of accumulating multiple metabolic diseases simultaneously, the researchers provide a concrete signal that preventive strategies, including glucose screening, blood pressure monitoring, and lifestyle counseling, could be tailored to menopause history. For the millions of women worldwide who experience late natural menopause, the message is not alarm but awareness: a longer reproductive lifespan may carry a metabolic bill that arrives later in life, and knowing that in advance is the first step toward paying it down early.

Subject of Research: The association between age at menopause and metabolic multimorbidity risk in Chinese postmenopausal women

Article Title: Age at menopause and major metabolic disorders among Chinese middle-aged and older women

Article References: Age at menopause and major metabolic disorders among Chinese middle-aged and older women. (n.d.). https://doi.org/10.1186/s12916-026-05225-9

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05225-9

Keywords: menopause, metabolic multimorbidity, diabetes, hypertension, dyslipidemia, women's health, China, CHARLS, estrogen exposure, aging, epidemiology, Cox proportional hazards

The research team was led by Stuart J. H. Biddle of the University of Southern Queensland and Daniel P. Bailey of Brunel University of London, working alongside colleagues from Brunel University of London, the University of Bedfordshire, University College London, the University of Leicester, and Curtin University. The collaboration brought together expertise spanning physical activity research, behavior change science, diabetes care, and physiotherapy. The team went beyond simply measuring whether participants sat less. As part of a process evaluation embedded within the trial, they asked the 35 intervention participants directly about the barriers they encountered and the strategies they attempted while trying to break up their sitting time. This qualitative lens is critical, because interventions that fail often fail for reasons that accelerometer data alone cannot explain. Numbers can show that sitting time did or did not fall, but only participants can articulate why, and those reasons are exactly what future interventions need to address.

The scale of the qualitative dataset was substantial. Using template analysis, a structured qualitative method in which coding frameworks are developed and refined against the data in iterative passes, the researchers analyzed 44 statements describing barriers, contributed by 18 participants, and 99 statements describing attempted behavior change strategies, contributed by 17 participants. Crucially, these statements were drawn from two separate time periods, three months and six months into the intervention, allowing the team to check whether the same themes held steady over time or shifted as the program progressed. This dual time-point design matters, because behavior change is rarely static. What feels manageable in the early weeks of a program can become harder as novelty fades, and obstacles that seem minor at first can accumulate into reasons for disengagement. By comparing themes across both windows, the researchers could assess whether the experience of trying to sit less was consistent or evolving.

What emerged was a remarkably consistent picture of obstruction. The barrier themes were similar at both the three-month and six-month assessments, falling into four broad categories. The first was fatigue and sleep, with participants reporting feelings such as drowsiness that made remaining upright or active feel unappealing. Tiredness is a familiar companion of diabetes, and it directly competes with the energy required to stand and move. The second was disability and health problems, reflecting the reality that many people with type 2 diabetes also manage other health conditions that make standing and moving more difficult. The third category was work-related barriers, encompassing both the demands of work tasks and the physical constraints of work facilities, such as desk-bound roles and environments not configured for standing or walking. The fourth was contextual barriers, a theme capturing social and environmental circumstances, from household routines to surroundings that simply did not invite movement.

These findings matter because sedentary behavior is not merely the absence of exercise. High volumes of sitting are associated with an increased risk of adverse health outcomes, and that risk is understood to be especially concerning for individuals with type 2 diabetes, whose metabolic systems are already compromised. Designing interventions that target sitting time, rather than only structured exercise, has therefore attracted growing attention in diabetes care. Yet designing such interventions requires knowing what participants are actually up against, day after day. An intervention can prescribe regular breaks from sitting with perfect logic, but if participants are battling drowsiness, painful health conditions, inflexible jobs, and unsupportive environments, the prescription collides with reality. The process evaluation was designed to surface exactly that collision, giving researchers a map of the terrain any future program would need to navigate.

The strategy themes reported by participants offered a counterpart to the barrier analysis, and they clustered around three behavioral approaches. The first involved ways to break up sitting itself, deliberately interrupting prolonged periods in a chair with other behaviors. The second centered on increasing incidental physical activity, the unplanned, everyday movement woven into daily routines. The third involved adding in purposeful physical activity, intentional exercise layered on top of daily life. Together, these strategies reveal that participants understood the core message of the intervention: the goal is substitution, replacing sitting with alternative postures and activities, rather than simply exercising more while otherwise remaining sedentary. That distinction is central to the science of sedentary behavior, because a person can meet exercise guidelines and still accumulate long, uninterrupted stretches of sitting that carry their own risks.

The alignment between barriers and strategies is instructive. Where fatigue and drowsiness undermined efforts to stand, participants could respond with low-effort movement rather than strenuous activity, suggesting that interventions should calibrate expectations to energy levels. Where work environments enforced sitting, participants attempted to carve out movement within constraints, a finding that points toward workplace-level environmental changes as complementary supports. And where health conditions limited mobility, the emphasis on gentle, incidental movement offered a realistic pathway that pure exercise prescriptions often miss. The fact that the same strategy themes appeared across both assessment periods suggests that participants had internalized a flexible repertoire rather than a rigid set of rules, adapting the same underlying principles to whatever circumstances they faced.

The study’s design also carries lessons for the field. As a feasibility trial, it was built to evaluate whether a remotely delivered sedentary behavior intervention could work in this population, and the process evaluation shows why such evaluations are indispensable. Remotely delivered interventions remove geographic barriers to participation but also strip away in-person supervision, leaving participants to translate guidance into action on their own. Understanding that participants gravitate toward breaking up sitting and boosting incidental activity, and that they repeatedly collide with fatigue, health limitations, and unsupportive environments, gives future trial designers concrete targets for refinement. Rather than guessing at what might help, designers can build directly on the barriers and strategies that participants themselves identified, strengthening the bridge between intervention content and everyday life.

The consistency of themes across the three- and six-month data points is arguably the study’s most reassuring signal. Behavior change research has long grappled with the problem of decay, in which strategies that work initially fade as novelty wears off. Here, the same core barriers and the same core strategies persisted across both assessment windows, suggesting that the intervention’s framework gave participants a stable vocabulary of tactics even as they continued to face familiar obstacles. Stability, in this context, is not stagnation; it indicates that the behavioral targets were durable and comprehensible enough to remain salient half a year into the program. It also suggests that the barriers participants faced were not transient inconveniences but ongoing features of their lives, which reinforces the case for interventions that plan for them from the outset rather than treating them as surprises.

For clinicians, public health practitioners, and the millions of people managing type 2 diabetes, the takeaways are refreshingly concrete. Reducing sitting time does not require heroic workouts; it requires substituting other behaviors for sitting, inserting short bouts of standing and movement into desk-bound days, and layering both incidental and purposeful physical activity on top of daily routines. But the study is equally clear that individual effort operates within a web of individual and contextual constraints: tired bodies, health conditions, rigid workplaces, and environments built for chairs. Future interventions that anticipate these barriers and equip participants with a repertoire of substitution strategies are more likely to succeed and, in doing so, to chip away at the sitting-driven risks that shadow life with type 2 diabetes. The authors suggest that such information may prove useful in future interventions to reduce sedentary behavior, and this study provides a detailed, participant-centered foundation for building them.

Subject of Research: Sedentary behaviour change: barriers and strategies reported by individuals with type 2 diabetes during a multi-component intervention

Article Title: Sedentary behaviour change: barriers and strategies reported by individuals with type 2 diabetes during a multi-component intervention

Article References: Biddle, S. J. H., Brierley, M. L., Chater, A. M., Edwardson, C. L., Castle, E., Hunt, E. R., & Bailey, D. P. (2026). Sedentary behaviour change: barriers and strategies reported by individuals with type 2 diabetes during a multi-component intervention. Journal of Activity, Sedentary and Sleep Behaviors. https://doi.org/10.1186/s44167-026-00112-3

Image Credits: AI Generated

DOI: 10.1186/s44167-026-00112-3

Keywords: Sedentary, behaviour, change, barriers, strategies, reported, individuals, type, diabetes, during, multi-component, intervention

The scale of the microbial contribution is difficult to overstate. The intestinal microbiota contains a gene pool approximately 150 times larger than the human genome, dominated by four major phyla: Bacteroides, Firmicutes, Proteobacteria and Actinomycetes. The ratio of Firmicutes to Bacteroidetes has emerged as a recurring biomarker of microbial imbalance, or dysbiosis, across conditions ranging from obesity to hypertension. In health, the community operates in eubiosis, a balanced state in which microbes signal to host cells, train the immune system, protect against pathogens and regulate nutrient metabolism. When that balance collapses, the review finds, the consequences ripple far beyond the gut wall.

Technically, the microbiota’s influence flows through a small set of chemically well-defined metabolites. Fermentation of undigested carbohydrates by saccharolytic bacteria such as Bifidobacteria, Bacteroides, Faecalibacterium and Roseburia yields the short-chain fatty acids acetate, propionate and butyrate. These molecules bind G-protein-coupled receptors including GPR41, GPR43 and GPR109A on enteroendocrine and immune cells, triggering cAMP/PKA signaling that drives secretion of the satiety hormones GLP-1 and PYY, and inhibiting histone deacetylases to promote anti-inflammatory regulatory T cells. Bile acids, deconjugated in the colon by organisms such as Bacteroides intestinalis, signal through the nuclear receptor FXR and the membrane receptor TGR5 to regulate lipid metabolism and glucose homeostasis. Meanwhile, microbial metabolism of choline, carnitine and betaine generates trimethylamine, which the liver converts to trimethylamine N-oxide, or TMAO, a compound now firmly linked to cardiovascular risk.

The cardiovascular findings are among the most striking. Hypertensive patients show significant decreases in microbial diversity and richness and a markedly elevated Firmicutes-to-Bacteroidetes ratio, and a meta-analysis of eighteen observational studies found blood TMAO concentrations associated with hypertension risk in a dose-dependent manner. Mechanistically, TMAO activates the PERK unfolded-protein response in endothelial cells, provoking NF-κB-mediated inflammation and vascular dysfunction, while in macrophages it drives foam cell formation through CD36 upregulation. Animal experiments reinforce causality: transplanting stool from hypertensive patients into germ-free mice raises blood pressure, and antibiotic-mediated restoration of the Bacteroidetes-to-Firmicutes ratio relieves hypertension in rats. Microbial hydrogen sulfide adds another layer, since deficiency of this vasorelaxant gas precedes the onset of high blood pressure in spontaneously hypertensive rats.

Atherosclerosis tells a parallel story. Bacterial DNA has been recovered from atherosclerotic plaques, indicating that microbes or their products can reach the vessel wall, and a metagenome-wide association study found Enterobacter aerogenes significantly enriched in patients with atherosclerosis. Dysbiosis increases intestinal permeability, allowing lipopolysaccharide to enter the circulation and fuel vascular inflammation. Elevated TMAO accelerates macrophage-to-foam-cell conversion, impairs endothelial function and promotes platelet reactivity and thrombosis, while a second microbial metabolite, phenylacetylglutamine, enhances clotting through adrenergic G-protein-coupled receptors. Counterbalancing these harmful pathways, bile acids activate FXR to suppress inflammatory cytokine expression in monocytes and macrophages, and short-chain fatty acids promote vasorelaxation through cAMP-dependent signaling in the vascular endothelium.

The gut-brain axis occupies perhaps the most provocative territory in the review. In Parkinson’s disease, patients consistently show depletion of butyrate-producing genera such as Prevotella, Faecalibacterium and Butyricicella alongside expansions of Bifidobacteria and Enterococcus. Reduced short-chain fatty acid and ghrelin signaling appears to promote alpha-synuclein aggregation and overactivation of microglia, the brain’s resident immune cells. In a landmark germ-free mouse experiment, fecal microbiota transplanted from Parkinson’s patients worsened alpha-synuclein-driven motor deficits more than transplants from healthy donors, providing some of the strongest causal evidence that gut microbes can shape neurodegeneration. Alzheimer’s disease follows a similar logic: dysbiosis elevates pro-inflammatory taxa such as Escherichia and Shigella, and accumulation of microbial-derived phenylalanine and isoleucine expands pro-inflammatory Th1 cells that inflame the central nervous system.

Experimental interventions in Alzheimer’s models are particularly encouraging. APPPS1 mice raised germ-free show markedly reduced beta-amyloid deposition and microglial activation compared with conventionally raised animals, and transferring healthy microbiota into Alzheimer’s model mice improves amyloid and tau pathology, cognitive performance and glial reactivity. The prebiotic R13 has been shown to restrain amyloid aggregation in the gastrointestinal tract by modulating the C/EBPβ-AEP pathway, while the drug sodium oligomannate, or GV-971, remodels gut flora to prevent peripheral amino acid buildup and reduce neuroinflammation. The authors caution, however, that most human studies in Parkinson’s and Alzheimer’s are cross-sectional, confounded by medication such as levodopa, and marked by inconsistent findings across cohorts, so longitudinal and standardized studies remain essential.

Metabolic disease occupies the largest share of the evidence. In obesity, the microbiota of affected individuals shows reduced diversity with losses of Akkermansia muciniphila, Bacteroides and Faecalibacterium prausnitzii, and germ-free mice receiving obese-donor microbiota gain more fat than those receiving lean-donor communities. Short-chain fatty acids counter obesity through two routes: stimulating GLP-1 and PYY release to suppress appetite, and upregulating thermogenic and lipid-oxidation proteins including PPARγ, PGC1α, UCP1 and CPT-1. In diabetes, both type 1 and type 2 forms are associated with diminished microbial diversity, and microbiota-derived metabolites such as lipopolysaccharide and flagellin disrupt epithelial tight junctions and fuel insulin resistance. Non-alcoholic fatty liver disease completes the picture through the gut-liver axis, in which increased intestinal permeability permits endotoxin and even microbially produced endogenous ethanol to reach the liver, while butyrate activates the AMPK pathway to curb hepatic lipogenesis.

On the gastrointestinal front, inflammatory bowel disease features a characteristic collapse of Firmicutes and expansion of Proteobacteria, with fungal overgrowth also documented in Crohn’s disease, and transfer of dysbiotic microbes into germ-free mice reproduces colitis. In colorectal cancer, organisms such as Peptostreptococcus anaerobius and Fusobacterium nucleatum activate oncogenic signaling and suppress anti-tumor immunity, while microbial gallic acid can even flip mutant p53 between tumor-suppressive and cancer-promoting behavior depending on gut location. The review closes with a therapeutic roadmap: personalized probiotics guided by metagenomic sequencing, polyphenol- and fiber-rich diets to boost short-chain fatty acid production, narrow-spectrum antimicrobials that spare beneficial taxa, and fecal microbiota transplantation, which already cures recurrent Clostridium difficile infection and is being explored for obesity, inflammatory bowel disease and metabolic syndrome. The authors argue that integrating bioinformatics, organoid models and artificial intelligence will be the key to translating this microbial science from correlation into clinical practice.

Beyond the disease-specific findings, the review underscores how malleable the gut ecosystem is across a human lifetime. Composition shifts from birth through aging, and population studies consistently identify diet, geography, systemic illness and pharmaceutical exposure as dominant determinants of which taxa flourish. Antibiotic overuse emerges as a particular concern, since broad-spectrum agents can destabilize the eubiotic equilibrium and predispose the host to systemic disease, whereas a nutritious diet rich in fermentable substrates sustains communities that benefit the host.

The metabolic versatility of the resident microbes is central to this story. Colon-dwelling organisms preferentially consume carbohydrates that escape digestion in the upper tract, and when those substrates run short, bacteria switch to alternative energy sources that generate potentially harmful metabolites. This substrate-dependence explains why dietary pattern, not merely caloric intake, shapes the chemical signals reaching host tissues. The archaeon Methanobrevibacter smithii illustrates the ecosystem’s complexity: by converting hydrogen produced through bacterial fermentation into methane, it fine-tunes the fermentation environment in ways that influence overall energy harvest.

Microbes also participate in processing compounds the host cannot handle alone, including xenobiotics and drugs, a capacity with direct pharmacological implications. The review notes that microbial enzymes can alter drug metabolism, which may partly explain inter-individual variation in therapeutic response and adverse effects, an area the authors suggest deserves deeper integration into personalized medicine.

Methodologically, the field has had to overcome substantial obstacles. Early estimates of intestinal species richness were undercounts, driven by the difficulty of culturing many obligate anaerobes outside the body. Molecular and metagenomic approaches have since revealed the true diversity, and the authors argue that combining bioinformatics with organoid systems and machine learning will be essential to move from associative observations toward mechanistic, predictive models of microbe-host interaction.

On translation, the review strikes a measured tone. Fecal microbiota transplantation already stands as the clearest clinical success, effectively curing recurrent Clostridium difficile infection, while narrower applications for metabolic syndrome and inflammatory bowel disease remain under investigation. Personalized probiotics selected through sequencing, prebiotic fibers that feed beneficial saccharolytic taxa, polyphenol-rich diets, and narrow-spectrum antimicrobials designed to spare commensals together form a therapeutic toolkit that the authors believe could eventually shift clinical practice from treating dysbiosis after it appears toward maintaining eubiosis preventively, provided that rigorous longitudinal human studies validate the causal pathways suggested by animal work.

Subject of Research: Roles of the human gut microbiota and its metabolites in metabolic, neurodegenerative, cardiovascular and gastrointestinal diseases

Article Title: Roles of human gut microbiota in metabolic, neurodegenerative, cardiovascular and gastrointestinal diseases

Article References: Joshi, D., Chauhan, K., Oberoi, H. S., Kumar, D., & Taneja, N. K. (2026). Roles of human gut microbiota in metabolic, neurodegenerative, cardiovascular and gastrointestinal diseases. Discover Biotechnology, 3(1), Article 8. https://doi.org/10.1007/s44340-026-00053-2

Image Credits: AI Generated

DOI: 10.1007/s44340-026-00053-2

Keywords: gut microbiota, dysbiosis, short-chain fatty acids, TMAO, gut-brain axis, Parkinson's disease, Alzheimer's disease, hypertension, atherosclerosis, obesity, diabetes, fecal microbiota transplantation

Hepatocellular carcinoma, the most common form of primary liver cancer, is a disease deeply entangled with metabolism. Most patients develop it on a backdrop of cirrhosis, chronic inflammation, and often obesity or diabetes, all of which reshape body composition in ways that standard measures like body mass index cannot capture. Over the past decade, computed tomography has emerged as the gold standard for assessing body composition in cancer care, because the same scans used to stage tumors and monitor response also allow precise quantification of skeletal muscle and adipose tissue at a single anatomical level, typically the third lumbar vertebra. Abnormal patterns on these scans, particularly muscle depletion and distorted fat distribution, have increasingly been linked to worse outcomes across many cancer types. What has remained unclear is whether these measurements, which capture a moving target, remain meaningful as a patient’s body wastes away during months of therapy.

The research team, led by Salvatore Corallo of the University of Pavia and Fondazione IRCCS Policlinico San Matteo together with Margherita Rimini of IRCCS San Raffaele Hospital and Andrea Casadei-Gardini, set out to answer two questions at once. First, how does body composition at the start of treatment influence survival and the risk of dose-limiting toxicities in patients with advanced hepatocellular carcinoma? Second, how does body composition change over the course of treatment, and do those changes alter the predictive value of the baseline measurements? Their retrospective analysis included 113 patients with advanced disease who received first-line systemic therapy, roughly seventy percent treated with tyrosine kinase inhibitors and thirty percent with immune checkpoint inhibitors, primarily the widely used combination of atezolizumab and bevacizumab that has become the standard of care for unresectable disease.

The technical heart of the study lies in quantitative CT analysis performed at two time points: baseline, before treatment began, and the moment of best radiologic response. At the level of the third lumbar vertebra, the researchers measured the lumbar skeletal muscle index, a cross-sectional muscle area normalized for height, alongside separate indices for visceral and subcutaneous adipose tissue. From the two fat measurements they derived the visceral-to-subcutaneous adipose tissue ratio, abbreviated VSR, a dimensionless number that expresses the balance between metabolically active internal fat and the more inert peripheral fat depot. This distinction is biologically important. Visceral adipose tissue is a hormonally active organ that secretes inflammatory cytokines, adipokines, and free fatty acids directly into the portal circulation that drains into the liver, fueling inflammation, insulin resistance, and in the context of cirrhosis, a hostile metabolic environment. Subcutaneous fat, by contrast, has a comparatively quiescent secretory profile, and a high proportion of visceral relative to subcutaneous fat is considered a marker of metabolically adverse adiposity.

The statistical analysis relied on Cox proportional hazards regression to model the relationship between body composition variables and survival outcomes, complemented by generalized linear models for the toxicity endpoint. In univariable analyses, two features stood out: a high visceral-to-subcutaneous adipose tissue ratio and muscle depletion, both of which predicted poor survival. When the investigators moved to bivariable models adjusted for established prognostic factors in advanced hepatocellular carcinoma, the association between elevated VSR and reduced survival held firm, indicating that the ratio carries prognostic information that is not simply a proxy for tumor burden, liver function, or other clinical variables. The strength of the effect was striking. Patients with a higher ratio, meaning a greater share of their fat packed into the visceral compartment, fared substantially worse than those whose fat was distributed more toward the subcutaneous depot.

Perhaps the most clinically consequential result concerns toxicity. Elevated VSR was associated with a significantly increased incidence of dose-limiting toxicities, with a hazard ratio of 1.16 per unit increase in the ratio, a ninety-five percent confidence interval of 1.08 to 1.26, and a p-value below 0.001. Dose-limiting toxicities are the severe adverse events that force clinicians to interrupt treatment, reduce doses, or abandon a regimen altogether, and they are a major reason why patients with advanced liver cancer fail to derive full benefit from otherwise effective drugs. A pre-treatment scan that identifies patients at high risk of such events could in principle guide closer monitoring, prophylactic supportive care, nutritional intervention, or earlier consideration of alternative regimens. The magnitude of the hazard ratio may appear modest per unit, but because VSR is a continuous variable spanning a wide range across patients, the cumulative difference in risk between the lowest and highest ratios is substantial.

The longitudinal component of the study delivered an equally important insight. Over the course of treatment, most patients lost both muscle and fat, as expected in advanced cancer, where cachexia and the metabolic side effects of therapy progressively erode body stores. Yet when the researchers recalculated the visceral-to-subcutaneous ratio at the time of best radiologic response, they found that it had remained essentially stable even as the absolute tissue quantities declined. This stability proved decisive for the ratio’s predictive value. At the follow-up time point, high VSR remained associated with poorer outcomes, with hazard ratios of 1.37 for progression-free survival and 1.12 for overall survival, both statistically significant at p below 0.001. In other words, the ratio behaved as a time-stable trait, a fixed characteristic of an individual’s metabolic constitution rather than a fluctuating state, which is precisely the quality that makes a biomarker trustworthy for repeated clinical use.

This property sets VSR apart from other body composition metrics that the field has pursued. Absolute muscle area and fat area shrink under the combined pressures of malignancy, inflammation, reduced intake, and drug toxicity, so measurements taken at different times are difficult to compare and their prognostic meaning drifts. A ratio, by contrast, normalizes one compartment against another, largely canceling out the generalized wasting that afflicts nearly all these patients. The study’s authors emphasize that this time stability is what allows VSR to function as a robust, repeatable predictor, and they frame it as a candidate for integration into the nutritional and prognostic assessment of patients with advanced hepatocellular carcinoma, pending validation in larger and more diverse cohorts.

The findings also resonate with a growing literature on the paradoxical role of adiposity in liver cancer prognosis. Prior work has shown that adipose tissue distribution predicts the prognosis of cirrhotic patients undergoing surgical resection for hepatocellular carcinoma, that different body composition patterns affect outcomes under immunotherapy in ways that confound expectations based on body mass index alone, and that clinical-adipometric nomograms can help predict tumor response to transarterial chemoembolization. The new study adds a unifying thread to this scattered evidence by proposing a single, stable, easily computed index that captures the metabolically relevant dimension of fat biology. The putative mechanisms are plausible: visceral fat’s portal drainage delivers inflammatory and immunomodulatory mediators directly to the diseased liver, potentially promoting tumor progression, undermining hepatic drug metabolism, and amplifying the systemic inflammation that heightens vulnerability to treatment-related injury.

The researchers are careful about the limits of their work. The study was retrospective, single-country, and modest in sample size, and it spanned two different classes of systemic therapy, which introduces heterogeneity even though the results were adjusted for relevant prognostic factors. The authors state explicitly that validation in larger studies is needed before VSR can be recommended for routine clinical decision-making. Nevertheless, the appeal of the approach is hard to overstate. Every patient with hepatocellular carcinoma undergoes serial abdominal CT as part of standard care, and the software to segment visceral and subcutaneous fat at the lumbar level is already available in most radiology departments. No additional radiation, cost, blood draw, or biopsy is required. A measurement that is essentially free, stable over time, and predictive of both the length of life and the quality of that life under treatment represents exactly the kind of low-hanging fruit that oncology nutrition research has long promised.

If the results are confirmed, the implications could extend beyond hepatocellular carcinoma to other cancers in which body composition shapes treatment tolerance, and they could reframe how clinicians think about obesity in oncology. Two patients with identical body mass index may carry radically different metabolic risk depending on the distribution of their fat, and the visceral-to-subcutaneous ratio offers a way to see that difference on a scan that would otherwise be read only for tumor response. For now, the message for the field is that the information needed to anticipate who will struggle with advanced liver cancer therapy may already be sitting, unexamined, on the picture archiving systems of cancer centers around the world.

The study, titled “Type 2 Diabetes and Longitudinal Changes in Cortical and Trabecular Bone Density, Microarchitecture, and Strength: The Framingham Study,” examined how the skeleton changes over time in older adults with and without type 2 diabetes. The research team used advanced bone imaging to measure not only bone density, but also the architecture and mechanical properties of two distinct parts of bone: cortical bone, the hard outer shell, and trabecular bone, the porous, lattice-like tissue inside.

“Bone density alone does not tell the whole story,” said senior author Elizabeth J. Samelson, PhD, principal investigator of the National Institutes of Health-funded project. People with type 2 diabetes often have bones that appear denser when measured using conventional techniques, yet they experience more fractures than people without diabetes. This apparent contradiction, sometimes called the diabetes bone paradox, has led scientists to investigate whether changes in the quality and organization of bone may be more important than bone mass alone.

The researchers initially expected adults with type 2 diabetes to show greater losses in bone density, microarchitecture, and strength during follow-up. Instead, the longitudinal analysis found that changes in bone were broadly similar between older adults with and without the disease. The result suggests that the elevated fracture risk associated with type 2 diabetes may emerge through pathways that are not captured by conventional measures of bone loss or by changes in the structural properties assessed in this study.

The imaging approach allowed the scientists to analyze cortical and trabecular bone separately. Cortical bone provides much of the skeleton’s resistance to bending and impact, while trabecular bone helps distribute forces through the spine, hips, and other load-bearing regions. Microarchitecture refers to features such as the thickness, spacing, and connectivity of these structures. Even subtle changes can affect how efficiently bone absorbs energy, but the study did not find a diabetes-related pattern of accelerated deterioration in these measures over time.

The study’s findings do not mean that bone health is irrelevant for people with type 2 diabetes. Rather, they indicate that fracture susceptibility may depend on a broader combination of skeletal and non-skeletal factors. Diabetes can affect vision, balance, muscle function, nerve sensation, and reaction time, all of which may increase the likelihood of falling. In addition, complications such as peripheral neuropathy can reduce awareness of foot position and uneven surfaces, potentially making falls more frequent or more severe.

The mechanical behavior of bone may also be influenced by properties that are difficult to measure with standard imaging. Long-term exposure to elevated blood glucose can promote the formation of advanced glycation end products, chemical compounds that accumulate in tissues and may alter the flexibility of collagen. Bone is a composite material made from mineral crystals embedded in a collagen-rich matrix, and changes to that matrix could affect how bone resists cracks even when bone density remains normal or high. The present study underscores the need to investigate these material-level properties more closely.

Alyssa B. Dufour, PhD, lead author and associate scientist at the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, said the team expected to observe greater changes in bone microstructure and strength among participants with type 2 diabetes. Instead, the similar rates of bone loss in the two groups suggest that clinicians and researchers should avoid treating bone density as a complete measure of fracture risk in diabetes. A person may have relatively dense bones while remaining vulnerable because of impaired balance, falls, altered bone material quality, or other disease-related factors.

The work was conducted by investigators from Hebrew SeniorLife, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston University, the University of Calgary, and Cardiovascular Engineering, Inc., using data from the Framingham Heart Study. Funding came from the National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Heart, Lung, and Blood Institute. By showing that similar longitudinal bone changes can coexist with different fracture risks, the study adds an important piece to the growing scientific picture of diabetes-related skeletal fragility and may encourage more comprehensive approaches to fracture prevention in older adults.

Subject of Research: People

Article Title: Type 2 Diabetes and Longitudinal Changes in Cortical and Trabecular Bone Density, Microarchitecture, and Strength: The Framingham Study

News Publication Date: 5-Aug-2026

Web References: Diabetes Care article: https://diabetesjournals.org/care/article-abstract/doi/10.2337/dc26-0846/172304/Type-2-Diabetes-and-Longitudinal-Changes-in?redirectedFrom=fulltext

References: DOI: 10.2337/dc26-0846

Keywords: Gerontology, type 2 diabetes, bone health, fracture risk, bone density, cortical bone, trabecular bone, microarchitecture, Framingham Study